“Psoriatic Arthritis Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Psoriatic Arthritis Market.
The Psoriatic Arthritis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Psoriatic Arthritis Pipeline Report:
Companies across the globe are diligently working toward developing novel Psoriatic Arthritis treatment therapies with a considerable amount of success over the years.
Psoriatic Arthritis companies working in the treatment market are ACELYRIN Inc., Sun Pharmaceutical Industries Limited, UCB Pharma, Ventyx Biosciences, Inc, Bristol-Myers Squibb, Aclaris Therapeutics, Inc., AbbVie, Novartis, Janssen Research & Development, LLC, MoonLake Immunotherapeutics AG, Affibody AB, Amgen, Eli Lilly and Company, PRA Health Sciences, and others, are developing therapies for the Psoriatic Arthritis treatment
Emerging Psoriatic Arthritis therapies in the different phases of clinical trials are- Izokibep, SUNPG18_07, Bimekizumab, VTX958, Deucravacitinib, ATI-450, Risankizumab, Upadacitinib, AIN457, Ustekinumab, Sonelokimab, and others are expected to have a significant impact on the Psoriatic Arthritis market in the coming years.
In November 2023, Takeda has reported achieving the primary endpoint in a Phase IIb trial of TAK-279 for patients with active psoriatic arthritis. This randomized, multicenter, double-blind, placebo-controlled, multiple-dose study (NCT05153148) assessed the efficacy, safety, and tolerability of TAK-279, an investigational oral allosteric tyrosine kinase 2 (TYK2) inhibitor with next-generation selectivity, in patients with active psoriatic arthritis.
In November 2023, Amgen (NASDAQ:AMGN) announced results from the global Phase 4 FOREMOST study evaluating Otezla® (apremilast) in patients with early oligoarticular psoriatic arthritis. FOREMOST is the first placebo-controlled study specifically designed to assess individuals with oligoarticular psoriatic arthritis of five years’ duration or less.
Psoriatic Arthritis Overview
Psoriatic arthritis is a form of inflammatory arthritis that affects some people who have psoriasis, a condition characterized by red, scaly skin patches. It can cause joint pain, stiffness, and swelling, and it often affects the fingers and toes.
Get a Free Sample PDF Report to know more about Psoriatic Arthritis Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/psoriatic-arthritis-pipeline-insight
Emerging Psoriatic Arthritis Drugs Under Different Phases of Clinical Development Include:
Izokibep: ACELYRIN Inc.
SUNPG18_07: Sun Pharmaceutical Industries Limited
Bimekizumab: UCB Pharma
VTX958: Ventyx Biosciences, Inc
Deucravacitinib: Bristol-Myers Squibb
ATI-450: Aclaris Therapeutics, Inc.
Risankizumab: AbbVie
Upadacitinib: AbbVie
AIN457: Novartis
Ustekinumab: Janssen Research & Development, LLC
Sonelokimab: MoonLake Immunotherapeutics AG
Psoriatic Arthritis Route of Administration
Psoriatic Arthritis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
Oral
Parenteral
Intravenous
Subcutaneous
Topical
Psoriatic Arthritis Molecule Type
Psoriatic Arthritis Products have been categorized under various Molecule types, such as
Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy
Psoriatic Arthritis Pipeline Therapeutics Assessment
Psoriatic Arthritis Assessment by Product Type
Psoriatic Arthritis By Stage and Product Type
Psoriatic Arthritis Assessment by Route of Administration
Psoriatic Arthritis By Stage and Route of Administration
Psoriatic Arthritis Assessment by Molecule Type
Psoriatic Arthritis by Stage and Molecule Type
DelveInsight’s Psoriatic Arthritis Report covers around 25+ products under different phases of clinical development like
Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration
Further Psoriatic Arthritis product details are provided in the report. Download the Psoriatic Arthritis pipeline report to learn more about the emerging Psoriatic Arthritis therapies
Some of the key companies in the Psoriatic Arthritis Therapeutics Market include:
Key companies developing therapies for Psoriatic Arthritis are – Pfizer Inc., Eisai Inc, UCB Biosciences Inc, Sanofi S.A., Otsuka Pharmaceutical, Sumitomo Dainippon Pharma Co, Johnson & Johnson, Celgene Corporation (Bristol-Myers Squibb), AbbVie Inc., and others.
Psoriatic Arthritis Pipeline Analysis:
The Psoriatic Arthritis pipeline report provides insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Psoriatic Arthritis with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Psoriatic Arthritis Treatment.
Psoriatic Arthritis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Psoriatic Arthritis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Psoriatic Arthritis market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Psoriatic Arthritis drugs and therapies
Scope of Psoriatic Arthritis Pipeline Drug Insight
Coverage: Global
Key Psoriatic Arthritis Companies: ACELYRIN Inc., Sun Pharmaceutical Industries Limited, UCB Pharma, Ventyx Biosciences, Inc, Bristol-Myers Squibb, Aclaris Therapeutics, Inc., AbbVie, Novartis, Janssen Research & Development, LLC, MoonLake Immunotherapeutics AG, Affibody AB, Amgen, Eli Lilly and Company, PRA Health Sciences, and others
Key Psoriatic Arthritis Therapies: Izokibep, SUNPG18_07, Bimekizumab, VTX958, Deucravacitinib, ATI-450, Risankizumab, Upadacitinib, AIN457, Ustekinumab, Sonelokimab, and others
Psoriatic Arthritis Therapeutic Assessment: Psoriatic Arthritis current marketed and Psoriatic Arthritis emerging therapies
Psoriatic Arthritis Market Dynamics: Psoriatic Arthritis market drivers and Psoriatic Arthritis market barriers
Request for Sample PDF Report for Psoriatic Arthritis Pipeline Assessment and clinical trials
Table of Contents
1. Psoriatic Arthritis Report Introduction
2. Psoriatic Arthritis Executive Summary
3. Psoriatic Arthritis Overview
4. Psoriatic Arthritis- Analytical Perspective In-depth Commercial Assessment
5. Psoriatic Arthritis Pipeline Therapeutics
6. Psoriatic Arthritis Late Stage Products (Phase II/III)
7. Psoriatic Arthritis Mid Stage Products (Phase II)
8. Psoriatic Arthritis Early Stage Products (Phase I)
9. Psoriatic Arthritis Preclinical Stage Products
10. Psoriatic Arthritis Therapeutics Assessment
11. Psoriatic Arthritis Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Psoriatic Arthritis Key Companies
14. Psoriatic Arthritis Key Products
15. Psoriatic Arthritis Unmet Needs
16 . Psoriatic Arthritis Market Drivers and Barriers
17. Psoriatic Arthritis Future Perspectives and Conclusion
18. Psoriatic Arthritis Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media ContactCompany Name: DelveInsightContact Person: Gaurav BoraEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432 City: AlbanyState: New YorkCountry: United StatesWebsite: https://www.delveinsight.com/
